Bonds & fixed income
IBBQInvescoINDEX
Invesco Nasdaq Biotechnology ETF
$35.38+2.01% vs prior close
263752-WK
Price through Oct 27, 2026 · Flows through Oct 26, 2026. Figures use the latest available records, not a live quote. Fund details retrieved Oct 27, 2026. Holdings snapshot retrieved Oct 27, 2026.
The fund generally will invest at least 90% of its total assets in the securities that comprise the index. Strictly in accordance with its guidelines and mandated procedures, Nasdaq compiles the underlying index, which is a modified market capitalization weighted index that is designed to measure the performance of securities listed on the Nasdaq Stock Market that are classified as either biotechnology or pharmaceutical companies. The index may include securities of large-, mid- and small-capitalization companies. The fund is non-diversified.
IBBQ price
Source: Market tape, daily closes; price return, distributions not reinvested
Table
| Date | IBBQ close |
|---|---|
| Jul 27, 2026 | $32.42 |
| Jul 28, 2026 | $32.76 |
| Jul 29, 2026 | $32.41 |
| Jul 30, 2026 | $32.70 |
| Jul 31, 2026 | $32.10 |
| Aug 3, 2026 | $31.98 |
| Aug 4, 2026 | $32.71 |
| Aug 5, 2026 | $32.93 |
| Aug 6, 2026 | $33.11 |
| Aug 7, 2026 | $33.72 |
| Aug 10, 2026 | $34.10 |
| Aug 11, 2026 | $34.05 |
| Aug 12, 2026 | $34.20 |
| Aug 13, 2026 | $33.91 |
| Aug 14, 2026 | $33.81 |
| Aug 17, 2026 | $34.30 |
| Aug 18, 2026 | $34.62 |
| Aug 19, 2026 | $36.82 |
| Aug 20, 2026 | $35.80 |
| Aug 21, 2026 | $36.29 |
| Aug 24, 2026 | $36.11 |
| Aug 25, 2026 | $36.80 |
| Aug 26, 2026 | $36.57 |
| Aug 27, 2026 | $36.45 |
| Aug 28, 2026 | $35.47 |
| Aug 31, 2026 | $35.47 |
| Sep 1, 2026 | $35.79 |
| Sep 2, 2026 | $36.30 |
| Sep 3, 2026 | $36.26 |
| Sep 4, 2026 | $36.05 |
| Sep 8, 2026 | $35.20 |
| Sep 9, 2026 | $34.93 |
| Sep 10, 2026 | $34.41 |
| Sep 11, 2026 | $34.47 |
| Sep 14, 2026 | $34.82 |
| Sep 15, 2026 | $34.25 |
| Sep 16, 2026 | $34.36 |
| Sep 17, 2026 | $35.13 |
| Sep 18, 2026 | $34.69 |
| Sep 21, 2026 | $34.85 |
| Sep 22, 2026 | $35.40 |
| Sep 23, 2026 | $34.76 |
| Sep 24, 2026 | $34.97 |
| Sep 25, 2026 | $35.00 |
| Sep 28, 2026 | $35.28 |
| Sep 29, 2026 | $35.24 |
| Sep 30, 2026 | $35.14 |
| Oct 1, 2026 | $34.42 |
| Oct 2, 2026 | $34.37 |
| Oct 5, 2026 | $34.75 |
| Oct 6, 2026 | $33.90 |
| Oct 7, 2026 | $34.01 |
| Oct 8, 2026 | $33.62 |
| Oct 9, 2026 | $34.62 |
| Oct 12, 2026 | $34.25 |
| Oct 13, 2026 | $33.43 |
| Oct 14, 2026 | $33.93 |
| Oct 15, 2026 | $34.66 |
| Oct 16, 2026 | $33.72 |
| Oct 19, 2026 | $34.00 |
| Oct 20, 2026 | $35.17 |
| Oct 21, 2026 | $35.25 |
| Oct 22, 2026 | $34.92 |
| Oct 23, 2026 | $34.52 |
| Oct 26, 2026 | $34.68 |
| Oct 27, 2026 | $35.38 |
Weekly net flows, 3M
Net inflow over the range: +$35M
- Inflow / above zero
- Outflow / below zero
Source: Daily creation and redemption records
Show as table
| Label | Value ($) |
|---|---|
| Jul 27 | $0 |
| Aug 3 | $960K |
| Aug 10 | $1.4M |
| Aug 17 | $7.2M |
| Aug 24 | $4M |
| Aug 31 | $1.1M |
| Sep 7 | $1.1M |
| Sep 14 | $0 |
| Sep 21 | $5.3M |
| Sep 28 | $6M |
| Oct 5 | $4.5M |
| Oct 12 | $1M |
| Oct 19 | $2.5M |
| Oct 26 | $0 |
The desk’s read
Money keeps arriving — +$14M of net inflows over the past month, about 12.1% of the fund's asset base, while the price has returned +24.6% so far this year. At 0.19% a year it is not the cheapest way in — XLV has a reported fee of 0.09%.
COMPOSED FROM THE FUND’S OWN DAILY RECORDS · UPDATED WITH EACH REFRESH
$116Massets under management
0.19%expense ratio · $19 per $10,000 a year
+$14Mnet flow, trailing month
52Kavg daily volume, 30 days
219holdings · US-domiciled
2021listed June 11, 2021 · beta 0.76
The book at a glance
CELL SIZE IS PORTFOLIO WEIGHT · COLOR IS THE CHANGE IN THE LATEST AVAILABLE SNAPSHOT · TOP 40 POSITIONS
Holdings
| # | Holding | Weight | Price | Day | 52-wk | |
|---|---|---|---|---|---|---|
| 1 | GILDGILEAD SCIENCES | 8.80% | $159.08 | +0.2% | ||
| 2 | AMGNAMGEN | 8.40% | $447.95 | +0.7% | ||
| 3 | VRTXVERTEX PHARMACEUTICALS | 7.72% | $521.03 | +0.7% | ||
| 4 | MRNAMODERNA | 5.27% | $207.97 | +4.6% | ||
| 5 | REGNREGENERON PHARMACEUTICALS | 5.42% | $816.10 | +1.0% | ||
| 6 | ILMNILLUMINA | 2.72% | $279.47 | +3.1% | ||
| 7 | RVMDREVOLUTION MEDICINES | 2.62% | $186.22 | +1.3% | ||
| 8 | BIIBBIOGEN | 2.48% | $252.73 | +0.2% | ||
| 9 | ALNYALNYLAM PHARMACEUTICALS | 2.02% | $226.79 | -0.4% | ||
| 10 | RPRXROYALTY PHARMA | 1.92% | $65.28 | +0.8% | ||
| 11 | ROIVROIVANT SCIENCES | 1.73% | $36.54 | +1.4% | ||
| 12 | UTHRUNITED THERAPEUTICS | 1.69% | $591.20 | -0.3% | ||
| 13 | ARGXARGENX SE | 1.57% | $882.48 | +1.5% | ||
| 14 | GHGUARDANT HEALTH | 1.54% | $178.06 | +2.8% | ||
| 15 | INCYINCYTE | 1.53% | $116.60 | +2.9% |
The full book, free with one sign-in.
Top 15 positions are open to everyone. Sign in once and every fund’s complete holdings — plus watchlists and flow alerts — unlock across the network.
Sign in to see all 219Sector weights
- Healthcare100%
- Health Technology97.86%
- Commercial Services1.89%
- Health Services0.23%
Source: Portfolio composition, latest disclosure
Show as table
| Item | Value (%) |
|---|---|
| Healthcare | 100% |
| Health Technology | 97.86% |
| Commercial Services | 1.89% |
| Health Services | 0.23% |
Country weights
- United States88.95%
- United Kingdom5.32%
- France1.49%
- Germany0.9%
- China0.88%
- Denmark0.86%
- Switzerland0.45%
- Canada0.4%
Source: Portfolio composition, latest disclosure
Show as table
| Item | Value (%) |
|---|---|
| United States | 88.95% |
| United Kingdom | 5.32% |
| France | 1.49% |
| Germany | 0.9% |
| China | 0.88% |
| Denmark | 0.86% |
| Switzerland | 0.45% |
| Canada | 0.4% |
Performance
| 1 week | +0.4% |
| 1 month | +1.1% |
| 3 months | +9.1% |
| 6 months | +20.6% |
| YTD | +24.6% |
| 1 year | +34.7% |
| 3 years | — |
PRICE RETURN, DISTRIBUTIONS NOT REINVESTED
Net flows
| 1 week | +$2M |
| 1 month | +$14M |
| 3 months | +$35M |
| YTD | +$57M |
| 1 year | +$57M |
CREATION/REDEMPTION DOLLARS, DAILY RECORDS
Monthly net flows
- Inflow / above zero
- Outflow / below zero
Source: Daily creation/redemption records, trailing twelve months
Show as table
| Label | Value ($) |
|---|---|
| Aug | $220K |
| Sep | $960K |
| Oct | $750K |
| Feb | $26.7M |
| Mar | $0 |
| Apr | −$7.5M |
| May | $0 |
| Jun | −$930K |
| Jul | $3.6M |
| Aug | $13.5M |
| Sep | $12.3M |
| Oct | $9.1M |
The risk read
28%realized volatility, 30 days (annualized)
22%realized volatility, 1 year
-9.2%deepest fall from a peak, 1 year
-3.9%latest close versus that peak
The top holding is 8.8% of the book; the top ten carry 47%. Spread across 248+ names, it behaves like roughly 30 equally-weighted positions.
VOLATILITY & DRAWDOWN FROM THE DAILY TAPE · CONCENTRATION FROM THE LATEST DISCLOSED BOOK
Options tape
—calls · latest snapshot
—puts · latest snapshot
—put/call ratio
27Kshares traded
| Most-traded holdings, options premium | Bullish | Bearish |
|---|---|---|
| MRNA MODERNA | $52M | $53M |
| AMGN AMGEN | $64M | $2M |
| INSM INSMED | $8M | $5M |
| TEM TEMPUS AI INC | $4M | $3M |
| IOVA IOVANCE BIOTHERAPEUTICS | $2M | $2M |
TODAY’S OPTIONS PREMIUM IN THE FUND’S UNDERLYING NAMES
The case against IBBQ
Due diligence cuts both ways. These funds sit on the same shelf and beat IBBQ on at least one dimension that matters — the fee, the asset base, or where the money is going.
| Fund | Fee | Assets | Flow, 1M | The case | |
|---|---|---|---|---|---|
| SPDW SPDR Portfolio Developed World ex-US ETF | 0.03% | $40.7B | +$609M | -16bp on fee · 353× the assets · +$609M in over the month | Head-to-head |
| BBUS JPMorgan BetaBuilders U.S. Equity ETF | 0.02% | $9.6B | +$187M | -17bp on fee · 83× the assets · +$187M in over the month | Head-to-head |
| SPMD State Street SPDR Portfolio S&P 400 Mid Cap ETF | 0.03% | $18.4B | +$199M | -16bp on fee · 159× the assets · +$199M in over the month | Head-to-head |
| SPYG State Street SPDR Portfolio S&P 500 Growth ETF | 0.04% | $57.9B | +$717M | -15bp on fee · 501× the assets · +$717M in over the month | Head-to-head |
| SPTM State Street SPDR Portfolio S&P 1500 Composite Stock Market ETF | 0.03% | $14.2B | +$235M | -16bp on fee · 123× the assets · +$235M in over the month | Head-to-head |